Case presenting on 12 year old female patient having chief complain of lump in right breast since 3 months ; initially which was small in size later increase and reachs up to present size with no complain of pain in general and before menstruation and no any family history and in menstrual history cycle is regular but of 15 days and 5 days bleeding period and no any positive history and on examination having 7×6×3 cm lump palpable in right upper inner quadrant of breast and movable freely and has history of taking progesterone pill for short menstrual cycle ; so kindly give me full explained viva questions on this case ; and if there is any relationship between progesterone pill and fibroadenoma; and if there is relationship between short 15 days cycle of menstruation and fibroadenoma

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching PubMed

fibroadenoma progesterone hormonal influence breast

Reading File

Finding Sources

Reading File

Searching the Web

progesterone pills fibroadenoma breast growth association evidence

Loading Image

I now have all the information needed for a thorough viva answer. Let me compose the full response.

Viva Questions & Answers: 12-Year-Old Female with Right Breast Lump (Fibroadenoma)

Sources: Schwartz's Principles of Surgery 11e; Berek & Novak's Gynecology; Mulholland & Greenfield's Surgery 7e

SECTION 1: INTRODUCTION AND DIAGNOSIS

Q1. What is your diagnosis and why?

Most likely diagnosis: Juvenile (Giant) Fibroadenoma of the right breast.

Reasoning:

Age 12, early reproductive years (peak age 10-25)
Lump is firm, smooth, freely mobile (no fixation, no skin tethering, no nipple retraction)
No pain (fibroadenomas classically non-tender)
No inflammatory signs
Rapidly enlarging to 7x6x3 cm - this qualifies as a giant fibroadenoma (>5 cm by most definitions, some use >3 cm)
No family history of breast malignancy
Regular menstrual cycle

The diagnosis falls within the ANDI (Aberrations of Normal Development and Involution) classification - a fibroadenoma in the early reproductive years is an aberration of normal lobular development, not a malignancy. - Schwartz's Principles of Surgery, p. 578

Q2. What is the ANDI classification? Where does this case fit?

ANDI places benign breast conditions along a spectrum from Normal → Disorder → Disease, across three reproductive phases:

Period	Normal	Disorder	Disease
Early reproductive (15-25 y)	Lobular/stromal development	Fibroadenoma	Giant fibroadenoma, multiple fibroadenomas
Mature reproductive (25-40 y)	Cyclic hormonal changes	Cyclic mastalgia, nodularity	-
Involution (35-55 y)	Lobular/ductal involution	Macrocysts, sclerosing lesions	Epithelial hyperplasia with atypia

This 12-year-old patient falls at the disease end of the early reproductive period because the size (7 cm) constitutes a giant fibroadenoma. - Berek & Novak's Gynecology, p. 979-980

Q3. Define fibroadenoma. What type is this?

A fibroadenoma is a benign fibroepithelial tumor composed of both epithelial (glandular) and stromal (fibrous) elements. It is the most common benign tumor of the breast.

Classification relevant to this case:

Simple fibroadenoma: ≤3 cm, in women 15-35 years
Giant fibroadenoma: >5 cm (some define >3 cm); uncommon
Juvenile fibroadenoma: occurs in girls aged 10-18 years, can range 5-20 cm, rapid growth pattern
Complex fibroadenoma: fibroadenoma associated with sclerosing adenosis, papillary apocrine changes, ductal epithelial hyperplasia - slightly higher cancer risk

This case is a juvenile giant fibroadenoma given the patient's age (12) and size (7x6x3 cm). - Mulholland & Greenfield's Surgery 7e, p. 3904

Q4. What is the histopathology of fibroadenoma?

Microscopically:

Proliferation of both stromal and epithelial (glandular) components
Well-circumscribed with a pseudocapsule
Two architectural patterns:
- Intracanalicular: stromal proliferation compresses glands into slit-like spaces
- Pericanalicular: gland lumina remain open and round, surrounded by stroma
In older/postmenopausal lesions: calcifications may be present in stroma

Fibroadenoma (40x) - well-circumscribed benign tumor comprising both stromal and glandular elements. Note the characteristic branching pink/purple structures.

Fibroadenoma histology (40x) - Schwartz's Principles of Surgery

Q5. What are the clinical features of fibroadenoma? Do they match this case?

Classic features (all present in this case):

Feature	Expected	This Case
Age	15-25 y (juvenile: 10-18 y)	12 y ✓
Consistency	Firm, rubbery, smooth	Present ✓
Mobility	Freely mobile ("breast mouse")	Freely mobile ✓
Pain	Non-tender	No pain ✓
Skin changes	Absent	Absent ✓
Nipple retraction	Absent	Absent ✓
Family history	Not causally linked	Negative ✓

The term "breast mouse" is used because the tumor slips away under the examining fingers due to its free mobility. - Berek & Novak's Gynecology, p. 980

Q6. What is the quadrant classification of the breast?

The breast is divided into 4 quadrants by lines passing through the nipple:

Upper Outer Quadrant (UOQ) - most common site of breast pathology (~50% of cancers)
Upper Inner Quadrant (UIQ) - this patient's lump is here
Lower Outer Quadrant (LOQ)
Lower Inner Quadrant (LIQ)
Central/Subareolar area

The axillary tail of Spence extends from the upper outer quadrant toward the axilla. Fibroadenomas can occur in any quadrant.

SECTION 2: INVESTIGATIONS

Q7. How would you investigate this patient?

Triple Assessment is the gold standard for any breast lump:

Clinical examination (already done - freely mobile, non-tender, well-defined)
Imaging
- Ultrasound (preferred in young patients <30 y) - expect a well-defined, smooth, oblong, solid hypoechoic mass with clearly defined margins
- Mammography has limited utility in dense adolescent breast tissue; not routinely used in this age group
Tissue sampling (biopsy)
- Core needle biopsy (CNB) or FNAC (fine needle aspiration cytology)
- If imaging is classic for fibroadenoma in a young patient, biopsy may be deferred, but given the size (7 cm) and need to exclude phyllodes tumor, core biopsy is strongly recommended

Q8. What is the imaging finding of fibroadenoma on ultrasound?

Well-defined, smooth borders
Oblong/ovoid shape
Solid, homogeneous internal echotexture
Hypoechoic compared to surrounding breast tissue
May show posterior acoustic enhancement
No irregular margins, no microcalcifications (which would suggest malignancy)

Q9. What is the differential diagnosis?

Diagnosis	Features that differentiate
Juvenile fibroadenoma (most likely)	Age 10-18, rapid growth, freely mobile, non-tender
Phyllodes tumor	Often history of stable lump that suddenly enlarges; leaf-like architecture histologically; must always be excluded in large/growing lumps
Breast abscess	Tender, erythematous, fluctuant, fever
Lipoma	Soft, lobulated, non-glandular origin
Breast cyst	Fluctuant, often tender pre-menstrually; common >25 y
Carcinoma	Fixed, hard, irregular, skin changes, lymphadenopathy - very rare at age 12

Key exam point: The most important differential to exclude in this case is Phyllodes tumor, which may be clinically indistinguishable from a giant fibroadenoma and shares similar histological features. Histology is required to differentiate.

SECTION 3: MANAGEMENT

Q10. What is the management of this patient?

Given this is a 7 cm juvenile fibroadenoma (giant fibroadenoma) in a 12-year-old:

Surgical excision is indicated for the following reasons:

Size >3-5 cm (giant)
Rapid enlargement
Cosmetic distress (at this age, a 7 cm lump is cosmetically and psychologically significant)
Need to exclude phyllodes tumor

Surgical considerations:

Conservative excision preserving breast parenchyma - this is critical in a prepubertal/pubertal girl to avoid damaging the breast bud and future breast development
Incision choice: periareolar or along skin lines to minimize scarring
Send specimen for histopathology

If it were small (<3 cm) and classic: Conservative management with watchful waiting (serial ultrasound) is acceptable because:

15% regress spontaneously
75-85% remain stable
5-10% progress - Berek & Novak's Gynecology, p. 981

Q11. What are the risks of surgical excision in a 12-year-old?

Damage to the breast bud: surgery on a developing breast can impair normal breast development and cause asymmetry/deformity
Recurrence: fibroadenomas may recur, especially if incompletely excised
Scarring
The operating surgeon must be careful to excise the mass while preserving surrounding normal breast tissue, especially the retroareolar tissue - Mulholland & Greenfield's Surgery 7e

Q12. What is the natural history of fibroadenoma?

~15% regress spontaneously (involution)
~75-80% remain stable in size
Only 5-10% grow progressively
Fibroadenomas do not transform into malignancy (standard simple fibroadenomas carry no increased breast cancer risk)
In complex fibroadenomas, there is a marginally increased risk
In pregnancy/lactation, may enlarge due to hormonal influence and then regress postpartum - Berek & Novak's Gynecology, p. 981

SECTION 4: PROGESTERONE PILLS AND FIBROADENOMA

Q13. Is there a relationship between progesterone pills (taken for short menstrual cycle) and fibroadenoma?

This is an important and nuanced question. The relationship is complex and the evidence cuts both ways:

Fibroadenomas are estrogen-sensitive tumors:

It is well established that fibroadenomas are responsive to estrogen stimulation - they occur in premenopausal women, enlarge in pregnancy (high estrogen state), and regress after menopause (low estrogen state) - Berek & Novak's Gynecology, p. 980

Role of progesterone:

Fibroadenoma cells express both estrogen receptors (ER) and progesterone receptors (PR)
In recent (cellular, low-fibrosis) fibroadenomas, progesterone receptors are present and high. Progestogen therapy in these cases has actually been associated with regression of fibroadenomas in some older studies (Kuttenn et al., 1983)
A French cohort study found a positive association between progestin use and the evolution (growth/multiplication) of multiple fibroadenomas - progestins and multiple fibroadenomas study
Combined oral contraceptives (containing both estrogen and progestogen), however, have been shown in epidemiological studies to reduce the incidence of fibroadenoma by 30-50%, possibly by suppressing ovulation and stabilizing hormonal cycling

Verdict for this case:

The patient took progesterone alone (not combined OCP) for short menstrual cycle
Exogenous progestogens can influence fibroadenoma behavior via PR receptor stimulation
Whether this caused or accelerated her fibroadenoma cannot be stated definitively - the fibroadenoma may have developed independently in the background of her pubertal hormonal environment
However, progestin exposure is biologically plausible as a contributing factor to growth of an existing fibroadenoma given its receptor sensitivity
This is an area of ongoing research and the relationship is not definitively causal

SECTION 5: SHORT MENSTRUAL CYCLE AND FIBROADENOMA

Q14. Is there a relationship between a 15-day (short) menstrual cycle and fibroadenoma?

Normal menstrual cycle: 21-35 days. A cycle of 15 days is called polymenorrhea (abnormally frequent menstruation).

Physiological basis:

A short cycle means more frequent follicular phases - each follicular phase produces a surge of estrogen (estradiol)
Greater cumulative estrogen exposure over time = more frequent and prolonged estrogen stimulation of breast tissue
Fibroadenomas are estrogen-responsive - increased estrogen exposure promotes lobular proliferation, which underpins fibroadenoma formation
The peri-ovulatory estrogen surge also triggers progesterone from the corpus luteum - so short cycles = more frequent hormonal fluctuations

Implications for this patient:

15-day cycles mean approximately double the monthly estrogen surges compared to a normal 30-day cycle
This chronic, frequent hormonal stimulation of estrogen-sensitive breast stroma could plausibly drive or accelerate fibroadenoma growth
Short cycles are also often associated with a shortened or inadequate luteal phase, which means relative progesterone deficiency with relative estrogen excess - this state of estrogen dominance is linked to benign breast disease (fibrocystic disease, fibroadenomas)

Important note: This is a pathophysiological association, not a proven direct causation. No high-quality randomized data establishes that polymenorrhea directly causes fibroadenoma. However, the hormonal basis (estrogen-sensitivity of fibroadenoma + high estrogen burden from short cycles) is mechanistically sound.

Q15. Why did the treating doctor prescribe progesterone pills for the short cycle?

Short cycles (polymenorrhea) often reflect shortened follicular phase or anovulation with inadequate progesterone production
Progesterone supplementation helps lengthen the luteal phase and regularize the cycle
In gynecological practice, micronized progesterone or synthetic progestins are prescribed in the second half of the cycle to support cycle regulation
This is a common clinical approach for dysfunctional uterine bleeding and polymenorrhea in adolescents

SECTION 6: PHYLLODES TUMOR - MUST KNOW DISTINCTION

Q16. How do you differentiate fibroadenoma from phyllodes tumor clinically and histologically?

Feature	Fibroadenoma	Phyllodes Tumor
Age	15-35 y (juvenile: 10-18 y)	Late 30s-50s (but can be any age)
Growth	Slow, stable after 2-3 cm	Often stable then sudden rapid enlargement
Size	Usually 1-3 cm (giant if >3-5 cm)	Often large at presentation (can be >10 cm)
Consistency	Firm, rubbery	May be lobulated, cystic areas
Bilaterality	Rare	Rarely bilateral
Histology	Benign epithelium + stroma in balance	Leaf-like (phyllodes) stromal fronds, stromal overgrowth, mitoses in stromal cells
Malignant potential	None (simple)	Benign (60%), Borderline (20%), Malignant (20%)
Recurrence	Low	High if incompletely excised
Management	Excision or watchful waiting	Wide local excision with clear margins (even for benign)

This case is suspicious for phyllodes because of the large size (7 cm) and rapid enlargement in a 12-year-old - histopathology after excision is mandatory. - Berek & Novak's Gynecology, p. 981-982

SECTION 7: ADDITIONAL VIVA POINTS

Q17. What is the blood supply of the breast?

Medial: Internal thoracic (internal mammary) artery perforators
Lateral: Lateral thoracic artery (branch of axillary artery)
Superior: Thoracoacromial artery
Venous drainage parallels arterial supply; deep veins drain to axillary and internal mammary veins

The upper inner quadrant (as in this patient) is supplied primarily by the internal thoracic artery perforators.

Q18. What is the lymphatic drainage of the breast relevant to this case?

75% of lymph drains to axillary lymph nodes
Medial breast (including UIQ where this tumor is) drains to internal mammary nodes
Supraclavicular and infraclavicular nodes
Rotter's nodes (interpectoral)

For this patient (UIQ lump), the relevant nodal groups are the axillary AND internal mammary nodes.

Q19. Does fibroadenoma increase risk of breast cancer?

Simple fibroadenoma: No increased risk
Complex fibroadenoma (with sclerosing adenosis, apocrine changes, epithelial hyperplasia): ~1.5-2x increased risk compared to general population
Fibroadenoma occurring in a patient with a first-degree relative with breast cancer: risk is higher but still modest
Standard fibroadenoma does not undergo malignant transformation - Berek & Novak's Gynecology, p. 981

Q20. What would you counsel this patient and her parents?

Reassure - this is a benign condition, not cancer
Explain the diagnosis - a benign tumor of breast tissue, common in young girls
Surgery is recommended given the large size (7 cm) and need to exclude phyllodes tumor
Risk of breast bud damage will be minimized by careful surgery
Recurrence is possible and follow-up will be needed
Address the progesterone treatment - discuss with their gynecologist regarding continued need
Menstrual health: investigate further why cycles are only 15 days

Summary Table for Revision

Feature	Detail
Diagnosis	Juvenile giant fibroadenoma, right UIQ
Size	7x6x3 cm (giant = disease in ANDI)
Key clinical sign	Freely mobile, non-tender, no skin/nipple changes
Investigations	Triple assessment: clinical + ultrasound + core biopsy
Must exclude	Phyllodes tumor
Management	Surgical excision (conservative, breast-bud sparing)
Progesterone link	Biologically plausible (PR receptor expression); progestins may influence growth but evidence not definitively causal
Short cycle link	Polymenorrhea → increased estrogen exposure → promotes estrogen-sensitive tumor growth (mechanistically sound, not proven causal)
Cancer risk	Not increased for simple fibroadenoma
ANDI classification	Early reproductive years, disorder → disease (giant fibroadenoma)

Key References:

Schwartz's Principles of Surgery 11e, Chapter 17 (Benign Breast Disorders), pp. 578-582
Berek & Novak's Gynecology, Chapter 19 (Benign Breast Conditions), pp. 978-985
Mulholland & Greenfield's Surgery 7e, Chapter on Proliferative Breast Lesions, p. 3904
Progestins and multiple fibroadenoma evolution (PMC7354733)

This is a shared conversation. Sign in to Orris to start your own chat.